Corrigendum to “SGLT2 inhibitor therapy improves blood glucose but does not prevent diabetic bone disease in diabetic DBA/2J male mice” [Bone 82 (2016) 101–107](S8756328215002999)(10.1016/j.bone.2015.07.025);SGLT2 inhibitor therapy improves blood glucose but does not prevent diabetic bone disease in diabetic DBA/2J male mice

Bone

Volumn 82, Issue , 2016, Pages 101-107

  Thrailkill, Kathryn M ^a   Clay Bunn, R ^a   Nyman, Jeffry S ^b   Rettiganti, Mallikarjuna R ^c   Cockrell, Gael E ^c   Wahl, Elizabeth C ^c   Uppuganti, Sasidhar ^b   Lumpkin, Charles K ^c   Fowlkes, John L ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Canagliflozin; Cortical bone; Diabetic bone disease; Microarchitecture; Trabecular bone; Type 1 diabetes

Indexed keywords

CALCIUM; CANAGLIFLOZIN; GLUCOSE; PARATHYROID HORMONE; SODIUM GLUCOSE COTRANSPORTER 2; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; GLUCOSE BLOOD LEVEL; SLC5A2 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE BOWING; BONE DISEASE; BONE STRENGTH; BONE STRUCTURE; CALCIUM URINE LEVEL; COMPRESSION; CONTROLLED STUDY; CORTICAL BONE; CORTICAL THICKNESS (BONE); DBA 2 MOUSE; DIABETES MELLITUS; DIABETIC BONE DISEASE; DIAPHYSIS; DISEASE DURATION; DRUG EFFECT; DRUG EFFICACY; EXERCISE TEST; FEMUR; FRACTURE; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; HYPERGLYCEMIA; LUMBAR VERTEBRA; MALE; METAPHYSIS; MICRO-COMPUTED TOMOGRAPHY; MOUSE; MUSCULOSKELETAL SYSTEM PARAMETERS; NONHUMAN; OSTEOLYSIS; POROSITY; RIGIDITY; TRABECULAR BONE; TREATMENT DURATION; TREATMENT RESPONSE; ANIMAL; ANTAGONISTS AND INHIBITORS; BONE DISEASES; DBA MOUSE; DIABETES MELLITUS, EXPERIMENTAL; DRUG EFFECTS; METABOLISM;

ANIMALS; BLOOD GLUCOSE; BONE DISEASES; CANAGLIFLOZIN; DIABETES MELLITUS, EXPERIMENTAL; MALE; MICE; MICE, INBRED DBA; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 84954397733     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2016.11.021     Document Type: Erratum

References (24)

1. Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes-a meta-analysis. Osteoporos. Int. 2007, 18(4):427-444. (PubMed PMID: 17068657). 10.1007/s00198-006-0253-4.
2. Neumann T., Samann A., Lodes S., Kastner B., Franke S., Kiehntopf M., Hemmelmann C., Lehmann T., Muller U.A., Hein G., Wolf G. Glycaemic control is positively associated with prevalent fractures but not with bone mineral density in patients with Type 1 diabetes. Diabet. Med. 2011, 28(7):872-875. (PubMed PMID: 21395677). 10.1111/j.1464-5491.2011.03286.x.
3. Nigro S.C., Riche D.M., Pheng M., Baker W.L. Canagliflozin, a novel SGLT2 inhibitor for treatment of type 2 diabetes. Ann. Pharmacother. 2013, 47(10):1301-1311. (PubMed PMID: 24259694). 10.1177/1060028013503626.
4. Perkins B.A., Cherney D.Z., Partridge H., Soleymanlou N., Tschirhart H., Zinman B., Fagan N.M., Kaspers S., Woerle H.J., Broedl U.C., Johansen O.E. Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial. Diabetes Care 2014, 37(5):1480-1483. (PubMed PMID: 24595630). 10.2337/dc13-2338.
5. Sands A.T., Zambrowicz B.P., Rosenstock J., Lapuerta P., Bode B.W., Garg S.K., Buse J.B., Banks P., Heptulla R., Rendell M., Cefalu W.T., Strumph P. Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in type 1 diabetes. Diabetes Care 2015, (PubMed PMID: 26049551). 10.2337/dc14-2806.
6. Taylor S.I., Blau J.E., Rother K.I. Possible adverse effects of SGLT2 inhibitors on bone. Lancet Diabetes Endocrinol. 2015, 3(1):8-10. (PubMed PMID: 25523498). 10.1016/S2213-8587(14)70227-X.
7. Fowlkes J.L., Nyman J.S., Bunn R.C., Cockrell G.E., Wahl E.C., Rettiganti M.R., Lumpkin C.K., Thrailkill K.M. Effects of long-term doxycycline on bone quality and strength in diabetic male DBA/2J mice. Bone Rep. 2015, 1:16-19. (PubMed PMID: 25685827; PubMed Central PMCID: PMC4324548). 10.1016/j.bonr.2014.10.001.
8. Quarles L.D. Role of FGF23 in vitamin D and phosphate metabolism: implications in chronic kidney disease. Exp. Cell Res. 2012, 318(9):1040-1048. (PubMed PMID: 22421513; PubMed Central PMCID: PMC3336874). 10.1016/j.yexcr.2012.02.027.
9. Fowlkes J.L., Bunn R.C., Liu L., Wahl E.C., Coleman H.N., Cockrell G.E., Perrien D.S., Lumpkin C.K., Thrailkill K.M. Runt-related transcription factor 2 (RUNX2) and RUNX2-related osteogenic genes are down-regulated throughout osteogenesis in type 1 diabetes mellitus. Endocrinology 2008, 149(4):1697-1704. (PubMed PMID: 18162513; PubMed Central PMCID: PMC2276714). 10.1210/en.2007-1408.
10. Nyman J.S., Even J.L., Jo C.H., Herbert E.G., Murry M.R., Cockrell G.E., Wahl E.C., Bunn R.C., Lumpkin C.K., Fowlkes J.L., Thrailkill K.M. Increasing duration of type 1 diabetes perturbs the strength-structure relationship and increases brittleness of bone. Bone 2011, 48(4):733-740. (PubMed PMID: 21185416; PubMed Central PMCID: PMC3062641). 10.1016/j.bone.2010.12.016.
11. Brown I.R., McBain A.M., Chalmers J., Campbell I.W., Brown E.R., Lewis M.J. Sex difference in the relationship of calcium and magnesium excretion to glycaemic control in type 1 diabetes mellitus. Clin. Chim. Acta 1999, 283(1-2):119-128. (PubMed PMID: 10404736).
12. Isidro M.L., Ruano B. Bone disease in diabetes. Curr. Diabetes Rev. 2010, 6(3):144-155. (PubMed PMID: 20380629).
13. Malone J.I., Lowitt S., Duncan J.A., Shah S.C., Vargas A., Root A.W. Hypercalciuria, hyperphosphaturia, and growth retardation in children with diabetes mellitus. Pediatrics 1986, 78(2):298-304. (PubMed PMID: 3488537).
14. Santer R., Calado J. Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target. Clin. J. Am. Soc. Nephrol. 2010, 5(1):133-141. (PubMed PMID: 19965550). 10.2215/CJN.04010609.
15. Musso G., Gambino R., Cassader M., Pagano G. A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials. Ann. Med. 2012, 44(4):375-393. (PubMed PMID: 21495788). 10.3109/07853890.2011.560181.
16. Powell D.R., DaCosta C.M., Gay J., Ding Z.M., Smith M., Greer J., Doree D., Jeter-Jones S., Mseeh F., Rodriguez L.A., Harris A., Buhring L., Platt K.A., Vogel P., Brommage R., Shadoan M.K., Sands A.T., Zambrowicz B. Improved glycemic control in mice lacking Sglt1 and Sglt2. Am. J. Physiol. Endocrinol. Metab. 2013, 304(2):E117-E130. (PubMed PMID: 23149623). 10.1152/ajpendo.00439.2012.
17. Liu J.J., Lee T., DeFronzo R.A. Why do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans?. Diabetes 2012, 61(9):2199-2204. (PubMed PMID: 22923645; PubMed Central PMCID: PMC3425428). 10.2337/db12-0052.
18. Jurczak M.J., Lee H.Y., Birkenfeld A.L., Jornayvaz F.R., Frederick D.W., Pongratz R.L., Zhao X., Moeckel G.W., Samuel V.T., Whaley J.M., Shulman G.I., Kibbey R.G. SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function. Diabetes 2011, 60(3):890-898. (PubMed PMID: 21357472; PubMed Central PMCID: PMC3046850). 10.2337/db10-1328.
19. +-D-glucose cotransporter SGLT2 in rodents is kidney-specific and exhibits sex and species differences. Am. J. Physiol. Cell Physiol. 2012, 302(8):C1174-C1188. (PubMed Central PMCID: PMC3774553). 10.1152/ajpcell.00450.2011.
20. Vrhovac I., Balen Eror D., Klessen D., Burger C., Breljak D., Kraus O., Radovic N., Jadrijevic S., Aleksic I., Walles T., Sauvant C., Sabolic I., Koepsell H. Localizations of Na-d-glucose cotransporters SGLT1 and SGLT2 in human kidney and of SGLT1 in human small intestine, liver, lung, and heart. Pflugers Arch. - Eur. J. Physiol. 2014, (PubMed PMID: 25304002). 10.1007/s00424-014-1619-7.
21. Chen J., Williams S., Ho S., Loraine H., Hagan D., Whaley J.M., Feder J.N. Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members. Diabetes Therapy 2010, 1(2):57-92. (PubMed PMID: 22127746; PubMed Central PMCID: PMC3138482). 10.1007/s13300-010-0006-4.
22. Liang Y., Arakawa K., Ueta K., Matsushita Y., Kuriyama C., Martin T., Du F., Liu Y., Xu J., Conway B., Conway J., Polidori D., Ways K., Demarest K. Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models. PLoS One 2012, 7(2):e30555. (PubMed PMID: 22355316; PubMed Central PMCID: PMC3280264). 10.1371/journal.pone.0030555.
23. Powell D.R., DaCosta C.M., Smith M., Doree D., Harris A., Buhring L., Heydorn W., Nouraldeen A., Xiong W., Yalamanchili P., Mseeh F., Wilson A., Shadoan M., Zambrowicz B., Ding Z.M. Effect of LX4211 on glucose homeostasis and body composition in preclinical models. J. Pharmacol. Exp. Ther. 2014, 350(2):232-242. (PubMed PMID: 24849925). 10.1124/jpet.114.214304.
24. Napolitano A., Miller S., Murgatroyd P., Hussey E., Dobbins R., Bullmore E., Nunez D. Exploring glycosuria as a mechanism for weight and fat mass reduction. A pilot study with remogliflozin etabonate and sergliflozin etabonate in healthy obese subjects. J. Clin. Trans. Endocrinol. 2014, 1:e3-e8.